Nurix Therapeutics (NRIX) Projected to Post Earnings on Wednesday

Nurix Therapeutics (NASDAQ:NRIX) is anticipated to announce its earnings results before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $12.78 million for the quarter.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $10.47 on Wednesday. The firm has a 50-day moving average of $16.01 and a 200-day moving average of $20.16. Nurix Therapeutics has a 52-week low of $10.37 and a 52-week high of $29.56. The stock has a market cap of $794.54 million, a PE ratio of -3.62 and a beta of 2.18.

Analysts Set New Price Targets

NRIX has been the subject of a number of analyst reports. Stifel Nicolaus lifted their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Royal Bank of Canada lifted their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Leerink Partnrs raised Nurix Therapeutics to a “hold” rating in a report on Monday, March 17th. Morgan Stanley boosted their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. Finally, Needham & Company LLC reduced their price objective on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.88.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at $488,660.76. This trade represents a 14.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 in the last 90 days. 7.20% of the stock is owned by corporate insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.